A Case of Pulmonary Sarcomatoid Carcinoma with Pneumothorax After Bevacizumab-combined Chemotherapy

Kodama, Airi; Doi, Mihoko; Hamai, Kousuke; Funaki, Masamoto; Kamitsuna, Masakazu; Doi, Masao

doi:10.2482/haigan.52.1041

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is presumed that the delayed wound healing time of BEV is a contributing factor, thus indicating the BEV should be initiated carefully after its half-life (20 days) and even 28 days following surgery [9]. The other searched articles were on conservative treatment; 1 follow-up observation [10], 3 cases with drainage [11][12][13], and 1 pleurodesis [14]. While most reported the cessation of BEV use after pyopneumothorax developed and was treated, there is a reported case in which BEV continued to be administered without any recurrences of pneumothorax until the patient started suffering from disease progression [11].…”

Section: Case Reportmentioning

confidence: 99%

Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer

et al. 2015

View full text Add to dashboard Cite

Pyopneumothorax is a rare but troubling complication of bevacizumab. We herein report a case of pyopneumothorax in a patient with metastatic breast cancer during bevacizumab treatment. A 60-year-old female who was diagnosed with metastatic breast cancer (ER? , PgR? , HER2-, Ki67 \14 %, metastasized to lung, pleural, brain, subcutaneous tissue, and bone) was started on bevacizumab plus paclitaxel chemotherapy. Although the disease was well-controlled, pyopneumothorax was noted after 3 months of treatment and the chemotherapy was therefore stopped immediately. The pyopneumothorax was so intractable that no conservative treatment could successfully manage it. The patient underwent a radical operation using the technique of latissimus dorsi muscle transfer. The operation improved her general condition and lead to hormonal therapy. Our case indicates the successful management of a severe side effect of bevacizumab for a breast cancer patient.

show abstract

Section: Case Reportmentioning

confidence: 99%